The Washington Post and the Guardian won Pulitzer Prizes for public service for their coverage of the surveillance tactics of the U.S. National Security Agency.
Asthma, the chronic lung disease, costs New York state more than $1.3 billion annually in medical costs and lost productivity, Comptroller Thomas DiNapoli said.
The worst week for biotechnology shares since 2011 did little to dissuade bullish investors. In fact, it provided them with a prime buying opportunity.
In one corner of the U.S. equity market, investor enthusiasm is exceeding the frenzy of the Internet bubble.
At 4 years old, Edmond Michael Abdel-Nour can distinguish the sound of a bullet from that of a mortar hitting his Damascus neighborhood.
InterMune Inc. rose the most ever after its drug pirfenidone for a fatal lung disease met goals of a study expected to support U.S. approval.
Kamada Ltd.’s investors will find out by the end of this quarter whether they were right to bet on the maker of treatments for hereditary lung disease getting close to a major expansion in Europe.
MediWound Ltd., an Israeli biotech company, said it’s planning an initial public offering a week after Varonis Systems Inc. raised $105.6 million in an IPO in New York.
Gilead Sciences Inc ., the world’s biggest maker of AIDS drugs, said it is stopping a late-stage study of an experimental lung-disease therapy because it didn’t help patients with the condition, idiopathic pulmonary fibrosis.
U.S. stocks fell, with the Standard & Poor’s 500 failing to break a record for a second day, after data showed slower growth in home prices and a drop in consumer confidence.